Brilaroxazine’s Role in Treating Schizophrenia, with Larry Ereshefsky, PharmD

The phase 3 RECOVER trial found brilaroxazine at 50 mg and 15 mg significantly reduced symptoms of acute schizophrenia and had a well-tolerated safety profile. Brilaroxazine is a serotonin-dopamine system modulator targeting D2/3/4 and 5-HT1A/2A receptors as a partial agonist and 5-HT2B/7 receptors as an antagonist. It can also control inflammatory cytokines.
Patients on brilaroxazine 50 mg achieved a 10.1-point reduction compared to placebo in the PANSS score. They also had improvements in positive, negative, and negative marder symptoms, PANSS social cognition, excitement or agitation, PSP, CGI-S.
In an interview with HCPLive, Larry Ereshefsky, PharmD, the chief scientific officer at CenExcel Research and Follow the Molecule, discussed the efficacy and safety of brilaroxazine, as well as the next steps for research.
Key Time Stamps:
Efficacy of brilaroxazine: 00.07
Improvements in various schizophrenia symptom domains: 7:19
Effects of brilaroxazine on inflammatory cytokines: 9:16
Safety profile: 15:47
Next steps for research: 17:31
Read more:
Part 1: Efficacy of brilaroxazine for schizophrenia
www.hcplive.com/view/phase-3-...
Part 2: Safety profile of brilaroxazine for schizophrenia
www.hcplive.com/view/larry-er...
Part 3: Next steps for brilaroxazine research
www.hcplive.com/view/advancin...
#schizophrenia #acuteschizophrenia #RECOVER #phase3 #brilaroxazine